The manufacture of MoDC-based anti-tumor vaccines generally consists out of four basic steps: patient apheresis; monocyte selection; monocyte-to-DC differentiation using granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin (IL)-4; and DC maturation along with TAA loading [4]. This evidence concerns the gene CSF2 and neoplasm.